FDA Approves Innovative Daily Psoriasis Pill, Securing a $50 Million Milestone for Protagonist

Newark, Wednesday, 18 March 2026.
The FDA’s March 18, 2026, approval of ICOTYDE, a novel once-daily psoriasis pill, triggers an immediate $50 million payout for Protagonist Therapeutics, alongside substantial future royalty potential.